Cite
Discontinuation of BRAF/MEK-Directed Targeted Therapy after Complete Remission of Metastatic Melanoma—A Retrospective Multicenter ADOReg Study
MLA
Henner Stege, et al. “Discontinuation of BRAF/MEK-Directed Targeted Therapy after Complete Remission of Metastatic Melanoma—A Retrospective Multicenter ADOReg Study.” Cancers, vol. 13, no. 10, May 2021, p. 2312. EBSCOhost, https://doi.org/10.3390/cancers13102312.
APA
Henner Stege, Maximilian Haist, Michael Schultheis, Maria Isabel Fleischer, Peter Mohr, Friedegund Meier, Dirk Schadendorf, Selma Ugurel, Elisabeth Livingstone, Lisa Zimmer, Rudolf Herbst, Claudia Pföhler, Katharina Kähler, Michael Weichenthal, Patrick Terheyden, Dorothée Nashan, Dirk Debus, Martin Kaatz, Fabian Ziller, … Carmen Loquai. (2021). Discontinuation of BRAF/MEK-Directed Targeted Therapy after Complete Remission of Metastatic Melanoma—A Retrospective Multicenter ADOReg Study. Cancers, 13(10), 2312. https://doi.org/10.3390/cancers13102312
Chicago
Henner Stege, Maximilian Haist, Michael Schultheis, Maria Isabel Fleischer, Peter Mohr, Friedegund Meier, Dirk Schadendorf, et al. 2021. “Discontinuation of BRAF/MEK-Directed Targeted Therapy after Complete Remission of Metastatic Melanoma—A Retrospective Multicenter ADOReg Study.” Cancers 13 (10): 2312. doi:10.3390/cancers13102312.